OGT to Present at International Workshop on the Search for New IVD Biomarkers
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Oxford Gene Technology (OGT), provider of clinical genetics and diagnostic solutions to advance molecular medicine, has been invited to present at the British In Vitro Diagnostics Association (BIVDA) Trilateral Workshop: “Role and significance of in vitro diagnostics in the healthcare systems of the future”.
Hosted at the French Embassy in Berlin from June 16 - 17, the workshop will consist of a series of sessions and chaired discussions, presenting research in in-vitro diagnostics (IVD) applications. On June 17, Dr. John Anson, Vice President of Biomarker Discovery at OGT, will speak on ‘Screening for novel oncology biomarker panels using both DNA and protein microarrays’.
Dr. Anson’s presentation will explore how knowledge of the human genome and proteome can be used to design DNA and protein microarrays to screen for markers of cancers and autoimmune diseases.
Dr. Anson will also present the results from an internal study, demonstrating the ability to identify a set of biomarkers in serum samples that can distinguish between cancerous and non-cancerous prostate cells, with sensitivity and specificity levels above 90%. Such advances will lead to the generation of more accurate diagnostic tests with greater discriminatory power, offering improved patient outcomes.
Hosted at the French Embassy in Berlin from June 16 - 17, the workshop will consist of a series of sessions and chaired discussions, presenting research in in-vitro diagnostics (IVD) applications. On June 17, Dr. John Anson, Vice President of Biomarker Discovery at OGT, will speak on ‘Screening for novel oncology biomarker panels using both DNA and protein microarrays’.
Dr. Anson’s presentation will explore how knowledge of the human genome and proteome can be used to design DNA and protein microarrays to screen for markers of cancers and autoimmune diseases.
Dr. Anson will also present the results from an internal study, demonstrating the ability to identify a set of biomarkers in serum samples that can distinguish between cancerous and non-cancerous prostate cells, with sensitivity and specificity levels above 90%. Such advances will lead to the generation of more accurate diagnostic tests with greater discriminatory power, offering improved patient outcomes.
